Oncology Institute (DFPH) Receivables - Net (2020 - 2026)

Oncology Institute has reported Receivables - Net for 7 years, with the latest figure at $58.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 17.87% year-over-year to $58.1 million; the trailing twelve-month figure through Mar 2026 stood at $58.1 million (up 17.87% YoY), and the FY2025 full-year result was $59.0 million, up 22.06% from the prior year.
• Receivables - Net for Q1 2026 stood at $58.1 million, down from $59.0 million in the prior quarter.
• The five-year high for Receivables - Net was $59.6 million in Q3 2025, with the low at $24.5 million in Q1 2022.
• Historically, Receivables - Net has averaged $47.6 million across 5 years, with a median of $48.4 million in 2023.
• Annual changes were most pronounced in 2022 — Receivables - Net jumped 99.01% — and 2025, when it fell 16.07%.
• Oncology Institute's Receivables - Net stood at $39.8 million in 2022, then rose by 6.39% to $42.4 million in 2023, then grew by 14.11% to $48.3 million in 2024, then advanced by 22.06% to $59.0 million in 2025, then retreated by 1.46% to $58.1 million in 2026.
• The last three Receivables - Net figures came in at $58.1 million (Q1 2026), $59.0 million (Q4 2025), and $59.6 million (Q3 2025), per Business Quant data.